Key facts
- Peptinovo Biopharma’s last known valuation is $23.3M (Dec 2024).
- It has raised $1.3M across 2 recorded rounds; the latest was Seed Round ($1.3M) in Sep 2024.
- Notable investors include Keiretsu Forum, Invest Detroit Ventures, Michigan Economic Development, Alligator Bioscience, Biosciences Research and Commercialization Center — 9 tracked in total.
- Peptinovo Biopharma has filed 3 Form Ds with the SEC since 2021, most recently Dec 2024 ($1.3M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Peptinovo Biopharma
Funding rounds
2 roundsAbout Peptinovo Biopharma
Operator of a drug delivery company intended to improve cancer survival. The company helps in the discovery and development of chemotherapy drugs that have resulted in novel nanoparticle technology that safely carries stronger doses of proven drugs directly into cancer cells while keeping them away from healthy tissue, enabling patients with an increase in drug efficacy, decrease in toxicity, and improvement in cancer survival.
- Sector
- Healthcare
- HQ
- Ann Arbor, MI, United States
- Founded
- 2018
- Employees
- 10
- Website
- peptinovo.com/
- Ownership
- Privately Held (backing)
Peptinovo Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Peptinovo Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Peptinovo Biopharma in its N-PORT filings yet. We sweep new filings monthly.